Table 2.
Clinical characteristics, pattern of metastases and previous treatments in 51 patients treated with high-dose ifosfamide (HDIFO).
| n | % | |
|---|---|---|
| All | 51 | 100 |
| Age median, range (years) | 19 (7–68) | |
| ≥18 years | 30 | 59 |
| <18 years | 21 | 41 |
| Sex | ||
| male | 33 | 65 |
| female | 18 | 53 |
| ECOG | ||
| 0 | 47 | 92 |
| 1 | 4 | 8 |
| Line at HDIFO | ||
| 1 | 46 | 90 |
| ≥2 | 5 | 10 |
| Histology | ||
| Osteoblatstic | 38 | 74 |
| Chondroblastic | 6 | 12 |
| Other | 7 | 14 |
| Metastases at diagnosis or relapse | ||
| Diagnosis | 5 | 90 |
| Relapse | 46 | 10 |
| Median time from diagnosis to HD-IFO | ||
| <24 months | 29 | 57 |
| ≥24 months | 22 | 43 |
| Pattern of metastases | ||
| Lung | 35 | 68 |
| Bone | 3 | 6 |
| Multiple sites | 13 | 26 |
| Ifosfamide in pretreatment | ||
| yes | 32 | 63 |
| no | 19 | 37 |
| Previous metastasectomy | ||
| yes | 26 | 51 |
| no | 25 | 49 |
| Primary tumor histologic response | ||
| <90% | 23 | 45 |
| ≥90% | 24 | 47 |
| Not available | 4 | 8 |
pts = patients, HDIFO = high-dose Ifosfamide.